Drug | Disease | Trial | Any-grade neurotoxicity (%)* | Grade ≥3 neurotoxicity (%) | Steroids mandated for NT in trial protocol? |
Axicabtagene ciloleucel[1,2] | DLBCL | ZUMA-1 | 64 | 28 | Yes |
FL | ZUMA-5 | 77 | 11 | Yes | |
Brexucabtagene autoleucel[3] | MCL | ZUMA-2 | 63 | 31 | Yes |
Ciltacabtagene autoleucel[4] | MM | CARTITUDE-1 | 17 | 2 | Yes |
Idecabtagene vicleucel[5] | MM | KarMMa | 18 | 3 | Yes |
Lisocabtagene maraleucel[6] | DLBCL | TRANSEND NHL 001 | 30 | 10 | Yes |
Tisagenlecleucel[7,8] | DLBCL | JULIET | 21 | 12 | No |
B-ALL | ELIANA | 40 | 13 | No |
CAR-T: chimeric antigen receptor T; NT: neurotoxicity; DLBCL: diffuse large B cell lymphoma; CTCAE: Common Terminology Criteria for Adverse Events; FL: follicular lymphoma; MCL: mantle cell lymphoma; MM: multiple myeloma; B-ALL: B cell acute lymphoblastic leukemia; ASTCT: American Society for Transplantation and Cellular Therapy.
* Using CTCAE 4.03 grading system for neurotoxicity for all products except ciltacabtagene autoleucel, which used CTCAE 5.0 in phase 1b and ASTCT ICANS criteria in phase 2.